Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma P-tau217 and Amyloid PET in Cognitively Normal Population
NCT05164536Phase 1Completed
- Sponsor
- Invicro
- Start
- Aug 2021
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Invicro. Primary endpoint: Brain amyloid deposition by region using PET signal-to-noise ratio, SUVr at 1 year. Started Aug 2021; status: completed.
Beyond the preview
Go deeper on NCT05164536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164536.